Dr. Mobeen continues the discussion about infective endocarditis. In this short but important session he presents the management approach to acute infective endocarditis. He discusses the treatment approach when the patient is not acutely ill, when the patient is acutely ill, and when the culture and sensitivity is available and you know if the pathogen is methicillin sensitive or methicillin resistant.
* Grasp principles of bactericidal therapy in endocarditis management.
* Appreciate importance of sustained antibiotic levels.
* Differentiate treatment approaches for acutely ill versus stable patients.
* Identify empiric therapy options for Staphylococci and Streptococci.
* Understand dosing considerations for vancomycin and alternatives.
* Recognize definitive therapy choices for MSSA and MRSA infections.
Following answers are created by ChatGPT. Occasionally the answer may be harmful, incorrect, false, misleading, incomplete, or limited in knowledge of world. Please contact your doctor for all healthcare decisions. Also, double check the answer provided by the AI below.
In addition to the presenter, following authors may have helped with the content writing, review, or approval:
ACCME Accreditation Statement
The DrBeen Corp is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
AMA Credit Designation Statement
The DrBeen Corp designates this enduring material for a maximum of 0.25 AMA PRA Category 1
Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the
activity.
In accordance with the disclosure policies of DrBeen Corp and the ACCME (Accreditation Council for
Continuing Medical Education), we are committed to upholding principles of balance, independence,
objectivity, and scientific rigor in all of our Continuing Medical Education (CME) and Continuing
Education (CE) activities. These policies include the careful management and mitigation of any relevant
financial relationships with organizations that are not eligible.
All members of the Activity Planning Committee and presenters have disclosed their relevant financial
relationships. The DrBeen Corp CE Committee has thoroughly reviewed these disclosures and determined
that these relationships are not deemed inappropriate in the context of their respective presentations.
Additionally, they are found to be consistent with the educational objectives and the integrity of the
activity.
| Faculty | Disclosures |
|---|---|
| Dr. Mobeen Syed | Author declares no conflict of interest. |
No credit card information needed.
0.17 CME
Dr. Mobeen Syed
0.50 CME
Dr. Mobeen Syed
0.20 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.17 CME
Dr. Mobeen Syed
0.23 CME
Dr. Mobeen Syed
1.00 CME
Dr. Mobeen Syed
0.21 CME
Dr. Mobeen Syed
0.50 CME
Dr. Mobeen Syed
0.75 CME
Dr. Mobeen Syed
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.20 CME
Dr. Mobeen Syed
0.14 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.23 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.23 CME
Dr. Mobeen Syed
0.17 CME
Dr. Mobeen Syed
Dr. Mobeen Syed
Dr. Mobeen Syed
Dr. Mobeen Syed
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
Dr. Mobeen Syed
Dr. Mobeen Syed
Dr. Mobeen Syed
Dr. Mobeen Syed
0.13 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
Dr. Mobeen Syed
0.50 CME
Dr. Mobeen Syed
0.75 CME
Dr. Mobeen Syed
0.50 CME
Dr. Mobeen Syed
0.17 CME
Dr. Mobeen Syed
0.50 CME
Dr. Mobeen Syed
0.50 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.25 CME
Dr. Mobeen Syed
0.21 CME
Dr. Mobeen Syed
0.24 CME
Dr. Mobeen Syed
All information contained in and produced by DrBeen corp is provided for educational purposes only. This information should not be used for the diagnosis or treatment of any health problem or disease.
THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.
Click here for notice and disclaimer.
Write A New Comment
0 Comments